Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

27. April 2018 aktualisiert von: Pfizer

A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control

This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

259

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Deutschland
      • Mannheim, Deutschland, 68159
        • Zentralinstitut fuer Seelische Gesundheit
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49005
        • Municipal Establishment "Dnipropetrovsk Regional Clinical Hospital n.a. Mechnikov"
      • Dnipropetrovsk, Ukraine, 49115
        • Municipal Establishment "Dnipropetrovsk Regional Clinical Psychiatric Hospital"
      • Kyiv, Ukraine, 02660
        • Kyiv City Psychoneurological Hospital #2
      • Kyiv, Ukraine, 04080
        • Kyiv City Clinical Psychoneurological Hospital #1
      • Lugansk, Ukraine, 91045
        • Lugansk Regional Clinical Psychoneurological Hospital
      • Poltava, Ukraine, 36006
        • Poltava Regional Clinical Psychiatric Hospital n.a. O.F. Maltsev
      • Stepanivka, Kherson, Ukraine, 73488
        • Kherson Regional Psychiatric Hospital, Department #3
  • Vereinigte Staaten
    • Arkansas
      • Little Rock, Arkansas, Vereinigte Staaten, 72201
        • K & S Professional Research Services, LLC
    • California
      • Anaheim, California, Vereinigte Staaten, 92801
        • Leisure Court Center
      • Escondido, California, Vereinigte Staaten, 92025
        • Early Phase Investigational Center
      • Escondido, California, Vereinigte Staaten, 92025
        • Synergy Clinical Research Center Of Escondido
      • Garden Grove, California, Vereinigte Staaten, 92845
        • Collaborative Neuroscience Network, Inc.
      • Long Beach, California, Vereinigte Staaten, 90822
        • Long Beach VA Healthcare System
      • Long Beach, California, Vereinigte Staaten, 90806
        • Ocean View Psychiatric Health Facility
      • Orange, California, Vereinigte Staaten, 92868
        • University of California Irvine Medical Center
      • Paramount, California, Vereinigte Staaten, 90723
        • California Clinical Trials Medical Group
      • Paramount, California, Vereinigte Staaten, 90723
        • LaPaz Geropsychiatric Center
      • San Diego, California, Vereinigte Staaten, 92123
        • Sharp Mesa Vista Hospital
      • Santa Ana, California, Vereinigte Staaten, 92701
        • Neuropsychiatric Research Center of Orange County
      • Torrance, California, Vereinigte Staaten, 90502
        • Collaborative Neuroscience Network, Inc.
      • Torrance, California, Vereinigte Staaten, 90505
        • Del Amo Hospital
    • District of Columbia
      • Washington, District of Columbia, Vereinigte Staaten, 20016
        • Comprehensive Neuroscience, Incorporated
    • Florida
      • Bradenton, Florida, Vereinigte Staaten, 34208
        • Florida Clinical Research Center, LLC
      • Maitland, Florida, Vereinigte Staaten, 32751
        • Florida Clinical Research Center, LLC
      • Orlando, Florida, Vereinigte Staaten, 32810
        • Lakeside Behavioral Healthcare
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30308
        • Atlanta Center for Medical Research
    • Illinois
      • Hoffman Estates, Illinois, Vereinigte Staaten, 60169
        • Alexian Brothers Center for Psychiatric Research
      • Hoffman Estates, Illinois, Vereinigte Staaten, 60169
        • Alexian Brothers Behavioral Health Hospital
      • Hoffman Estates, Illinois, Vereinigte Staaten, 60169
        • Chinmay K. Patel, D.O.
    • Louisiana
      • Lake Charles, Louisiana, Vereinigte Staaten, 70629
        • Lake Charles Clinical Trials
      • Lake Charles, Louisiana, Vereinigte Staaten, 70601
        • Lake Charles Memorial Hospital
    • Maryland
      • Rockville, Maryland, Vereinigte Staaten, 20850
        • CBH Health, LLC
    • Missouri
      • Saint Louis, Missouri, Vereinigte Staaten, 63118
        • St. Louis Clinical Trials, LC
    • New Jersey
      • Willingboro, New Jersey, Vereinigte Staaten, 08046
        • CRI Worldwide, LLC
      • Willingboro, New Jersey, Vereinigte Staaten, 08046
        • Lourdes Medical Center of Burlington County
    • New York
      • Hollis, New York, Vereinigte Staaten, 11423
        • Comprehensive NeuroScience, Inc.
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19139
        • CRI Worldwide, LLC
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78754
        • Community Clinical Research
      • Austin, Texas, Vereinigte Staaten, 78731
        • FutureSearch Trials
      • Austin, Texas, Vereinigte Staaten, 78745
        • TexasNeuroRehab Center
      • DeSoto, Texas, Vereinigte Staaten, 75115
        • Insite clinical research
      • Houston, Texas, Vereinigte Staaten, 77007
        • Bayou City Research, Ltd.
      • Houston, Texas, Vereinigte Staaten, 77081
        • Behavioral Hospital - Bellaire
    • Washington
      • Kirkland, Washington, Vereinigte Staaten, 98033
        • Eastside Therapeutic Resource
      • Kirkland, Washington, Vereinigte Staaten, 98034
        • Fairfax Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Diagnosis of schizophrenia with acute exacerbation of illness
  • The current acute exacerbation of schizophrenia must be less than 4 weeks duration prior to the initial evaluation.

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant uncontrolled medical illness
  • Subjects with a current diagnosis of schizoaffective disorder, major depression, bipolar disorder, or obsessive compulsive disorder.
  • Subjects who meet Diagnostic and Statistical Manual-IV (DSM-IV)defined diagnostic criteria for psychoactive substance dependence (excluding nicotine dependence) within 12 months of screening or DSM-IV defined substance abuse within 3 months prior to screening.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo
Arzneimittel: Placebo
One tablet/capsule every 12 hours for 28 days
Experimental: PF-02545920 5 mg
Arzneimittel: PF-02545920
5 mg tablet every 12 hours for 28 days
Arzneimittel: PF-02545920
15 mg tablet every 12 hours for 28 days
Experimental: PF-02545920 15 mg
Arzneimittel: PF-02545920
5 mg tablet every 12 hours for 28 days
Arzneimittel: PF-02545920
15 mg tablet every 12 hours for 28 days
Aktiver Komparator: Risperidone 3 mg
Arzneimittel: Risperidone
3 mg capsule every 12 hours for 28 days
Andere Namen:
  • Rispertal

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4
Zeitfenster: Baseline, Week 4
PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS total score and ranges from 30 to 210; higher score indicates greater severity.
Baseline, Week 4
Proportion of Participants With Dystonia Adverse Events
Zeitfenster: Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
Participants were assessed for presence of symptoms for any one of the following: dystonia, oromandibular dystonia, and oculogyric crisis.
Baseline up to end of study (7 to 10 days after administration of last dose of study medication)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Positive, Negative, and General Subscales Score at Week 4
Zeitfenster: Baseline, Week 4
PANSS - positive, negative, and general subscales assesses positive, negative and general psychopathological symptoms associated with schizophrenia respectively. Seven (7) items each make up the positive scale (for example; delusions, conceptual disorganization, and hallucinatory behavior) and negative scale (for example; blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal) and 16 items make up the general scale (for example; somatic concern, anxiety, guilt feelings, mannerisms and posturing, motor retardation, uncooperativeness, disorientation, poor impulse control, pre-occupation). Each item is rated on a 7-point Likert scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total scores range for positive as well as negative subscale is 7 to 49 and for general subscale is 16 to 112; higher subscale score indicates greater severity.
Baseline, Week 4
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 4
Zeitfenster: Baseline, Week 4
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state. Clinician responded to a question "Considering your total clinical experience with this particular population, how mentally ill is your patient at this time?" on the following scores: 1 (normal - not ill at all), 2 (borderline mentally ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), 7 (among the most severely ill participants). Higher score = more affected.
Baseline, Week 4
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Marder Factors Score at Week 4
Zeitfenster: Baseline, Week 4
PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). PANSS Marder positive symptoms subscale consists of 8 items with total score equal to sum of 8 items ranging from 8-56; Marder negative symptoms subscale and Marder disorganized thoughts (Dis. Thought) subscale, each consists of 7 items with total score equal to sum of 7 items each, ranging from 7-49, Marder uncontrolled hostility/excitement (Uncon. Hos/Exc) subscale and Marder anxiety/depression (Anx/Dep) subscale, each consists of 4 items with total score equal to sum of 4 items each ranging from 4-28. Higher subscale score indicates greater severity.
Baseline, Week 4
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Derived Brief Psychiatric Rating Scale (BPRS) Core Score at Week 4
Zeitfenster: Baseline, Week 4
PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia. PANSS derived BPRS is an 18-item clinician rated scale which assesses symptoms such as hostility, suspiciousness, hallucinations, grandiosity, and a number of other psychiatric symptoms. Items scored on a 7-point scale (1=not present and 7=extremely severe), with higher score indicating greater severity of symptom. BPRS core score consists of 4 items (Conceptual disorganization, Hallucinatory behavior, Suspiciousness/persecution, Unusual thought content) with total score equal to sum of the 4 items, ranging from 4 to 28, with higher score indicating greater severity.
Baseline, Week 4
Clinical Global Impression - Improvement (CGI-I) Score
Zeitfenster: Week 4
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Clinician responded to a question: "Compared to your subject's condition at the beginning of treatment, how much has your subject changed?" Compared to Baseline (Day 1), improvement was defined as score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected.
Week 4
Change From Baseline in Global Assessment of Functioning (GAF) Score at Week 4
Zeitfenster: Baseline, Week 4
GAF is a 100-point, clinician rated single item scale that rates the severity of illness-related impairment in psychological, social and occupational functioning of participants on a hypothetical continuum of mental illness to mental health. The scale values range from 1 to 100 with lower score indicating greater severity of illness and is divided into 10 equal intervals (descriptors): from 1-10 (persistent danger of hurting self - serious suicidal acting with clear expectations of death) to 91-100 (superior functioning - no symptoms). Each descriptor has a nine-point range to allow for some variability of severity within the descriptor.
Baseline, Week 4
Treatment Satisfaction Questionnaire for Medication (TSQM) Score
Zeitfenster: Week 4
TSQM assesses the participant's level of satisfaction with study medication. It consists of a 14-item questionnaire which comprises of 3 specific scales (effectiveness, side effects, convenience) and 1 global satisfaction scale. Effectiveness, convenience and global satisfaction scale are rated on a 7-point scale (0= Extremely Dissatisfied, 1= Very Dissatisfied, 2= Dissatisfied, 3= Somewhat Satisfied, 4= Satisfied, 5= Very Satisfied, 6= Extremely Satisfied) and side effects are rated on a 5-point scale (0= Extremely Dissatisfied, 1=Very Dissatisfied, 2= Somewhat Dissatisfied, 3= Slightly Dissatisfied, 4= Not at all Dissatisfied). Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.
Week 4
Change From Baseline in Body Weight at Week 4
Zeitfenster: Baseline, Week 4
Baseline, Week 4
Change From Baseline in Abdominal Girth at Week 4
Zeitfenster: Baseline, Week 4
Baseline, Week 4
Number of Participants With Clinically Significant Findings in Vital Signs and Electrocardiogram (ECG)
Zeitfenster: Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
Clinically significant findings based on investigator's discretion were assessed in vital sign parameters (including pulse rate, blood pressure and body temperature) and ECG parameters (including respiratory rate, heart rate, PR interval, QRS interval, QT interval, QT corrected using Bazett's correction [QTcB] interval, and QT corrected using Fridericia's correction [QTcF]).
Baseline up to end of study (7 to 10 days after administration of last dose of study medication)
Number of Participants With Clinically Significant Changes in Physical Examinations
Zeitfenster: Screening, Week 4
Clinically significant findings in physical examinations based on investigator's discretion were assessed. Screening was the 7 day time (from Day -8 to Day -2) before dosing on Day 1. Number of participants with clinically significant changes in physical examinations compared to screening was assessed.
Screening, Week 4
Number of Participants With Laboratory Test Abnormalities
Zeitfenster: Screening up to end of study (7 to 10 days after administration of last dose of study medication)
Criteria for abnormality:hematology: hemoglobin, hematocrit, red blood cell count: less than(<) 0.8*lower limit of normal (LLN); mean corpuscular volume; mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration: <0.9*LLN,>1.1*upper limit of normal (ULN); platelets: <0.5*LLN,>1.75*ULN, white blood cell count: <0.6*LLN, >1.5*ULN; lymphocytes, total neutrophils: <0.8*LLN, >1.2*ULN; eosinophils, basophils, monocytes: >1.2*ULN; coagulation: activated partial thromboplastin time, prothrombin, prothrombin international ratio: >1.1*ULN; liver function: bilirubin: >1.5*ULN; aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase: >3.0*ULN; protein, albumin: <0.8*LLN></0>1.2*ULN; renal function:blood urea nitrogen,creatinine: >1.3*ULN; uric acid: >1.2*ULN; electrolytes: sodium, potassium, chloride, calcium, bicarbonate: <0.9*LLN,>1.1*ULN; urinalysis: pH<4.5, >8; glucose, protein, blood, ketones, urobilinogen, bilirubin, nitrite; Other(glucose: <0.6*LLN,>1.5*ULN)
Screening up to end of study (7 to 10 days after administration of last dose of study medication)
Number of Participants With Abnormal White Blood Cell (WBC) Count and Absolute Neutrophil Count (ANC)
Zeitfenster: Day 1 up to Week 4
Pre-defined criteria was established for WBC Count (less than 0.6 times the lower limit of normal) and absolute neutrophil count (less than 0.8 times the lower limit of normal) to define the values that would be identified as abnormal.
Day 1 up to Week 4
Number of Participants With Clinically Significant Laboratory Test Abnormalities for Fasting Insulin, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Cholesterol, Triglycerides, Hemoglobin Type A1c (HbA1c) and Prolactin
Zeitfenster: Day 1 up to Week 4
Clinically significant findings based on investigator's discretion were assessed in laboratory parameters (including fasting insulin, high-density lipoprotein [HDL], low-density lipoprotein [LDL], Cholesterol, Triglycerides, glycosylated hemoglobin type A1c [HbA1c] and Prolactin).
Day 1 up to Week 4
Change From Baseline in Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A) Parameter Scores at Week 4
Zeitfenster: Baseline, Week 4
ESRS-A is a clinician rated scale consisting of 24 items to assess severity of extra-pyramidal symptoms for following parameters: parkinsonism (10 items), dystonia (6 items), dyskinesia (6 items) and akathisia (2 items). Each item is scored on a 6-point Likert scale (0=absent, 1=minimal, 2=mild, 3=moderate, 4=severe, 5=extreme). Total score for a parameter is average of individual item scores included under the parameter, ranging from 0 to 5, with higher score = more affected.
Baseline, Week 4
Change From Baseline in Movement Disorder Burden Score for Dystonia (MDBS-D) at Week 4
Zeitfenster: Baseline, Week 4
MDBS-D score reflects the numbers and durations of movement disorder adverse events for dystonia, the severity of the events, required treatment, and the total number of days the participant received study treatment. MDBS-D score = (S * D * C)/TTD; where S= Movement Disorder Severity Score for Dystonia (possible values: 1 [mild]; 2 [moderate]; 3 [severe]), D=adverse event duration (in days), C=concomitant medication factor (C=1.5 if an anti-cholinergic or beta blocker is used for the treatment of a movement disorder; C=1 if no concomitant medication is used), TTD=total treatment days for the participant. Value for MDBS score may range from zero to infinity. A higher MDBS-D score indicates a greater movement disorder adverse event liability compared to baseline.
Baseline, Week 4
Number of Participants With Response to Columbia-Suicide Severity Rating Scale (C-SSRS)
Zeitfenster: Baseline, Week 1, 2, 3, 4, Follow-up (FU) (7 to 10 days after administration of last dose of study medication)
Data relevant to the assessment of suicidality is mapped to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) event codes. C-SSRS assesses whether participant experiences following: suicide attempt (Event code 2) (Response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (Event code 3) ("Yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), suicidal ideation (Event code 4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act without specific plan or with specific plan and intent), self-injurious behavior, no suicidal intent (Event code 7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior"). Number of participants with "Yes" response for above mentioned categories are assessed. Baseline is defined as the Week 0 measurement.
Baseline, Week 1, 2, 3, 4, Follow-up (FU) (7 to 10 days after administration of last dose of study medication)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Pfizer

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Oktober 2010

Primärer Abschluss (Tatsächlich)

1. August 2011

Studienabschluss (Tatsächlich)

1. August 2011

Studienanmeldedaten

Zuerst eingereicht

3. August 2010

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

3. August 2010

Zuerst gepostet (Schätzen)

4. August 2010

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

22. Mai 2018

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. April 2018

Zuletzt verifiziert

1. April 2018

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • A8241012
  • 2010-020764-38 (EudraCT-Nummer)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren